Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: A single center experience

Mutations in the tumor suppressor gene TP53 are detected in 5–10% of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes. TP53 mutations have been associated with complex karyotypes, therapy-related malignancies, lower response rates to cytotoxic chemotherapy, and an overall adv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leuk Lymphoma
Autors principals: Bewersdorf, Jan Philipp, Shallis, Rory M., Gowda, Lohith, Wei, Wei, Hager, Karl, Isufi, Iris, Kim, Tae Kon, Pillai, Manoj M., Seropian, Stuart, Podoltsev, Nikolai A., Gore, Steven D., Siddon, Alexa J., Zeidan, Amer M.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7603787/
https://ncbi.nlm.nih.gov/pubmed/32362171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1759051
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars